Clinical and biochemical markers in CIPN: A reappraisal |
| |
Affiliation: | 1. Moffitt Cancer Center, Tampa, FL, United States of America;2. University of South Florida, Tampa, FL, United States of America |
| |
Abstract: | The increased survival of cancer patients has raised growing public health concern on associated long-term consequences of antineoplastic treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is a primarily sensory polyneuropathy, which may be accompanied by pain, autonomic disturbances, and motor deficit. About 70% of treated cancer patients might develop CIPN during or after the completion of chemotherapy, and in most of them such complication persists after six months from the treatment. The definition of the potential risk of development and resolution of CIPN according to a clinical and biochemical profile would be certainly fundamental to tailor chemotherapy regimen and dosage on individual susceptibility. In recent years, patient-reported and clinician-related tools along with quality of life instruments have been featured as primary outcomes in clinical setting and randomized trials. New studies on metabolomics markers are further pursuing accurate and easily accessible indicators of peripheral nerve damage. The aim of this review is to outline the strengths and pitfalls of current knowledge on CIPN, and to provide a framework for future potential developments of standardized protocols involving clinical and biochemical markers for CIPN assessment and monitoring. |
| |
Keywords: | Chemotherapy Neurotoxicity Neurofilament light chain Markers Metabolomics CIPN" },{" #name" :" keyword" ," $" :{" id" :" kw0035" }," $$" :[{" #name" :" text" ," _" :" Chemotherapy-Induced Peripheral Neuropathy GWAS" },{" #name" :" keyword" ," $" :{" id" :" kw0045" }," $$" :[{" #name" :" text" ," _" :" Genome-Wide Association Studies SNP" },{" #name" :" keyword" ," $" :{" id" :" kw0055" }," $$" :[{" #name" :" text" ," _" :" Single-Nucleotide Polymorphism GSTP1" },{" #name" :" keyword" ," $" :{" id" :" kw0065" }," $$" :[{" #name" :" text" ," _" :" Glutathione-S-Transferase P1 GSTM1" },{" #name" :" keyword" ," $" :{" id" :" kw0075" }," $$" :[{" #name" :" text" ," _" :" Glutathione-S-Transferase M1 CMT1A" },{" #name" :" keyword" ," $" :{" id" :" kw0085" }," $$" :[{" #name" :" text" ," _" :" Charcot–Marie–Tooth disease type 1A ROS" },{" #name" :" keyword" ," $" :{" id" :" kw0095" }," $$" :[{" #name" :" text" ," _" :" Reactive Oxygen Species DRG" },{" #name" :" keyword" ," $" :{" id" :" kw0105" }," $$" :[{" #name" :" text" ," _" :" Dorsal Root Ganglia mDNA" },{" #name" :" keyword" ," $" :{" id" :" kw0115" }," $$" :[{" #name" :" text" ," _" :" mitochondrial DNA CaV2.2" },{" #name" :" keyword" ," $" :{" id" :" kw0125" }," $$" :[{" #name" :" text" ," _" :" N-type voltage-gated Ca2+ channels TRP" },{" #name" :" keyword" ," $" :{" id" :" kw0135" }," $$" :[{" #name" :" text" ," _" :" Transient Receptor Potential S1P" },{" #name" :" keyword" ," $" :{" id" :" kw0145" }," $$" :[{" #name" :" text" ," _" :" Sphingosine-1-Phosphate DH-S1P" },{" #name" :" keyword" ," $" :{" id" :" kw0155" }," $$" :[{" #name" :" text" ," _" :" Dihydrosphingosine-1-Phosphate ICIs" },{" #name" :" keyword" ," $" :{" id" :" kw0165" }," $$" :[{" #name" :" text" ," _" :" Immune Checkpoint Inhibitors CTC" },{" #name" :" keyword" ," $" :{" id" :" kw0175" }," $$" :[{" #name" :" text" ," _" :" Common Toxicity Criteria WHO" },{" #name" :" keyword" ," $" :{" id" :" kw0185" }," $$" :[{" #name" :" text" ," _" :" World Health Organization ECOG" },{" #name" :" keyword" ," $" :{" id" :" kw0195" }," $$" :[{" #name" :" text" ," _" :" Eastern Cooperative Oncology Group NCI-CTCAENational Cancer Institute" },{" #name" :" keyword" ," $" :{" id" :" kw0205" }," $$" :[{" #name" :" text" ," _" :" Common Terminology Criteria for Adverse Events ONTS" },{" #name" :" keyword" ," $" :{" id" :" kw0215" }," $$" :[{" #name" :" text" ," _" :" Oxaliplatin Neurological Toxicity Scale DEB-NTC" },{" #name" :" keyword" ," $" :{" id" :" kw0225" }," $$" :[{" #name" :" text" ," _" :" Neurotoxicity Criteria of Debiopharm PRO" },{" #name" :" keyword" ," $" :{" id" :" kw0235" }," $$" :[{" #name" :" text" ," _" :" Patient-Reported Outcome EORTC" },{" #name" :" keyword" ," $" :{" id" :" kw0245" }," $$" :[{" #name" :" text" ," _" :" European Organization for Research and Treatment of Cancer FACT/GOG NTX" },{" #name" :" keyword" ," $" :{" id" :" kw0255" }," $$" :[{" #name" :" text" ," _" :" Functional Assessment of Cancer Therapy/Gynecological Cancer Group Neurotoxicity questionnaire QoL" },{" #name" :" keyword" ," $" :{" id" :" kw0265" }," $$" :[{" #name" :" text" ," _" :" Quality Of Life MCID" },{" #name" :" keyword" ," $" :{" id" :" kw0275" }," $$" :[{" #name" :" text" ," _" :" Minimal Clinically Important Difference TNAS" },{" #name" :" keyword" ," $" :{" id" :" kw0285" }," $$" :[{" #name" :" text" ," _" :" Treatment-induced Neuropathy Assessment Scale PROCTCAE" },{" #name" :" keyword" ," $" :{" id" :" kw0295" }," $$" :[{" #name" :" text" ," _" :" Patient-Reported Outcomes Version of the National Cancer Institute Common Terminology Criteria for Adverse Events NSQ" },{" #name" :" keyword" ," $" :{" id" :" kw0305" }," $$" :[{" #name" :" text" ," _" :" Neuropathy Screening Question ICPNQ" },{" #name" :" keyword" ," $" :{" id" :" kw0315" }," $$" :[{" #name" :" text" ," _" :" Indication for Common Toxicity Criteria Grading of Peripheral Neuropathy Questionnaire PNQ" },{" #name" :" keyword" ," $" :{" id" :" kw0325" }," $$" :[{" #name" :" text" ," _" :" Patient Neurotoxicity Questionnaire CIPN-R-ODS" },{" #name" :" keyword" ," $" :{" id" :" kw0335" }," $$" :[{" #name" :" text" ," _" :" Rasch overall disability scale for CIPN CINQ" },{" #name" :" keyword" ," $" :{" id" :" kw0345" }," $$" :[{" #name" :" text" ," _" :" Chemotherapy-induced Neurotoxicity Questionnaire CIPNAT" },{" #name" :" keyword" ," $" :{" id" :" kw0355" }," $$" :[{" #name" :" text" ," _" :" Chemotherapy-induced peripheral neuropathy assessment tool OANQ" },{" #name" :" keyword" ," $" :{" id" :" kw0365" }," $$" :[{" #name" :" text" ," _" :" Oxaliplatin-associated neurotoxicity questionnaire SCIN" },{" #name" :" keyword" ," $" :{" id" :" kw0375" }," $$" :[{" #name" :" text" ," _" :" Scale for Chemotherapy-Induced long-term Neurotoxicity TNS" },{" #name" :" keyword" ," $" :{" id" :" kw0385" }," $$" :[{" #name" :" text" ," _" :" Total Neuropathy Score TNSr" },{" #name" :" keyword" ," $" :{" id" :" kw0395" }," $$" :[{" #name" :" text" ," _" :" TNS reduced version TNSc" },{" #name" :" keyword" ," $" :{" id" :" kw0405" }," $$" :[{" #name" :" text" ," _" :" TNS clinical version TNSr-SF" },{" #name" :" keyword" ," $" :{" id" :" kw0415" }," $$" :[{" #name" :" text" ," _" :" TNS short form mTNS" },{" #name" :" keyword" ," $" :{" id" :" kw0425" }," $$" :[{" #name" :" text" ," _" :" modified TNS RTTNSc" },{" #name" :" keyword" ," $" :{" id" :" kw0435" }," $$" :[{" #name" :" text" ," _" :" Rasch transformed TNSc NCS" },{" #name" :" keyword" ," $" :{" id" :" kw0445" }," $$" :[{" #name" :" text" ," _" :" Nerve conduction studies SAP" },{" #name" :" keyword" ," $" :{" id" :" kw0455" }," $$" :[{" #name" :" text" ," _" :" Sensory Action Potential CMAP" },{" #name" :" keyword" ," $" :{" id" :" kw0465" }," $$" :[{" #name" :" text" ," _" :" Compound Muscle Action Potential EMG" },{" #name" :" keyword" ," $" :{" id" :" kw0475" }," $$" :[{" #name" :" text" ," _" :" electromyography DSN" },{" #name" :" keyword" ," $" :{" id" :" kw0485" }," $$" :[{" #name" :" text" ," _" :" Dorsal Sural Nerve LEP" },{" #name" :" keyword" ," $" :{" id" :" kw0495" }," $$" :[{" #name" :" text" ," _" :" Laser-Evoked Potential CCM" },{" #name" :" keyword" ," $" :{" id" :" kw0505" }," $$" :[{" #name" :" text" ," _" :" Corneal Confocal Microscopy QSART" },{" #name" :" keyword" ," $" :{" id" :" kw0515" }," $$" :[{" #name" :" text" ," _" :" Quantitative Sudomotor Axon Reflex Test SSR" },{" #name" :" keyword" ," $" :{" id" :" kw0525" }," $$" :[{" #name" :" text" ," _" :" Sympathetic Skin Response QST" },{" #name" :" keyword" ," $" :{" id" :" kw0535" }," $$" :[{" #name" :" text" ," _" :" Quantitative Sensory Testing VDT" },{" #name" :" keyword" ," $" :{" id" :" kw0545" }," $$" :[{" #name" :" text" ," _" :" Vibration Detection Threshold IENF" },{" #name" :" keyword" ," $" :{" id" :" kw0555" }," $$" :[{" #name" :" text" ," _" :" Intraepidermal Nerve Fiber HRUS" },{" #name" :" keyword" ," $" :{" id" :" kw0565" }," $$" :[{" #name" :" text" ," _" :" High-Resolution Ultrasound CSA" },{" #name" :" keyword" ," $" :{" id" :" kw0575" }," $$" :[{" #name" :" text" ," _" :" Cross-Sectional Area MRN" },{" #name" :" keyword" ," $" :{" id" :" kw0585" }," $$" :[{" #name" :" text" ," _" :" Magnetic Resonance Neurography DTI" },{" #name" :" keyword" ," $" :{" id" :" kw0595" }," $$" :[{" #name" :" text" ," _" :" Diffusion Tensor Imaging FA" },{" #name" :" keyword" ," $" :{" id" :" kw0605" }," $$" :[{" #name" :" text" ," _" :" Fractional Anisotropy ADC" },{" #name" :" keyword" ," $" :{" id" :" kw0615" }," $$" :[{" #name" :" text" ," _" :" Apparent Diffusion Coefficient NfL" },{" #name" :" keyword" ," $" :{" id" :" kw0625" }," $$" :[{" #name" :" text" ," _" :" Neurofilament Light Chain TNS-PV" },{" #name" :" keyword" ," $" :{" id" :" kw0635" }," $$" :[{" #name" :" text" ," _" :" Total Neuropathy Score-Paediatric Vincristine |
本文献已被 ScienceDirect 等数据库收录! |
|